<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68954">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02088840</url>
  </required_header>
  <id_info>
    <org_study_id>SIGNB-GITMO-AMCLI-Survey</org_study_id>
    <nct_id>NCT02088840</nct_id>
  </id_info>
  <brief_title>Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant</brief_title>
  <acronym>GITMO-SIGNB</acronym>
  <official_title>A Prospective, Multicenter Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Autologous and Allogeneic Stem Cell Transplant.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Trapianto di Midollo Osseo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Trapianto di Midollo Osseo</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients undergoing autologous or allogeneic stem cell transplant (SCT) for any
      underlying disease will be monitored for severe infections by gram negative bacteria (SIGNB)
      during the engraftment period. The follow up will be stopped at 4 months from the day of
      transplant.  About 50 transplant centers will be involved in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe Infections by Gram Negative Bacteria (SIGNB) remain an important cause of morbidity
      and mortality in patients submitted to stem cell transplant particularly during engraftment
      while patients suffer of profound and prolonged neutropenia or during subsequent neutropenia
      periods related to loss of engraftment or viral infections. Epidemiology of severe
      infections by gram negative bacteria in stem cell transplant patients has varied in the last
      decades due to the increasing use of highly immunosuppressive stem cell transplant
      procedures, and in relation to global epidemiological phenomena involving several
      populations of immunocompromised patients including those submitted to stem cell transplant.

      The epidemiological evolution of severe infections by gram negative bacteria in
      immunocompromised patients is represented also by the emergence of infections caused by
      Gram-negative bacilli, in particular enterobacteria, resistant to several antimicrobials.
      Such pattern of susceptibility to antibacterial agents represents a challenging issue in the
      currents strategies of the use of antibiotics in prophylaxis or therapy.

      Despite an increasing attention to the clinical and therapeutic aspects of infection in stem
      cell transplant recipients, contrasting data are available on the incidence, microbiologic
      characteristics and clinical outcome of Severe Infections by Gram Negative Bacteria in this
      population.

      Management of patients submitted to stem cell transplant is frequently complicated by Severe
      Infections by Gram Negative Bacteria which may represent an obstacle to the transplant
      procedure. Severe Infections by Gram Negative Bacteria caused by microorganisms resistant to
      betalactamic antibiotics, which are the golden standard in the empirical antibacterial
      therapy of febrile neutropenia, represent a challenging problem. A revision of the
      antibacterial strategies and the consideration of new molecules with different antibacterial
      mechanism of action should be considered in the light of the emerging epidemiology.
      Antimicrobial prophylaxis, diagnostic approaches and antimicrobial therapy should be adapted
      to the infectious risk of the transplant population according to stem cell source,
      conditioning regimen and also to the infectious history before transplant. A crucial problem
      in the definition of these strategies is represented by the continuous change in the
      epidemiological patterns of infections as a result of the modification of risk factors in
      the transplant population and of the global epidemiology of hospital and community acquired
      infections. In particular the emergence of antibiotic resistant enterobacteria represents a
      serious problem which dramatically impacts on the antibacterial prophylaxis and treatments
      choices.

      The Investigator think that a continuous epidemiology survey is required in order to better
      define proper prevention, diagnostic and treatment approaches. A common problem in the
      infections control in immunocompromised populations is represented by the lack of
      epidemiological consciousness in the single centres and its relationship with the local
      policy in the use of antibacterial drugs. A prospective, multicenter survey of Severe
      Infections by Gram Negative Bacteria by antibiotic resistant pathogens, in particular
      enterobacteria, may be a useful tool to evaluate the epidemiological patterns of infections,
      their impact on the overall survival, and a critical analysis of the use of antibacterial
      drugs.

      The Investigator of this study think that the results of this survey may offer precious
      indications for the timely update of the prophylaxis, diagnosis and treatment strategies of
      Severe Infections by Gram Negative Bacteria in patients undergoing a stem cell transplant
      procedure.

      An important aspect of this study is represented by the involvement of both stem cell
      transplant and microbiology Italian societies, the GITMO Gruppo Italiano per il Trapianto di
      Midollo Osseo, cellule staminali emopoietiche e terapia cellulare and the AMCLI Associazione
      Microbiologi Clinici Italiani respectively, as a &quot;joint venture&quot; in the study of the
      clinical and microbiological aspects of Severe Infections by Gram Negative Bacteria in the
      autologous and allogeneic stem cell transplant populations. Investigators of both GITMO and
      AMCLI are involved in the design, writing and monitoring of the study and for each
      participating transplant center a clinician, responsible for the clinical data, and a
      microbiologist, responsible for the microbiological data, will be provided.

      The general objectives of this study are to prospectively evaluate the epidemiology of
      Severe Infections by Gram Negative Bacteria by antibiotic resistant pathogens in autologous
      and allogeneic stem cell transplant  patients during the engraftment period.

      All consecutive patients submitted to autologous or allogeneic stem cell transplant  for any
      underlying disease in about 50 Italian transplant centers will be prospectively monitored
      for  severe infections by gram negative bacteria during the engraftment period. The follow
      up will be stopped at 4 months from the day of transplant. Risk factors, incidence and
      prognostic factors of Severe Infections by Gram Negative Bacteria will be evaluated in the
      overall population and in subpopulations according to different transplant characteristics.
      Data on in vitro susceptibility patterns of the microorganisms and on the antibacterials
      used in prophylaxis and therapy will be collected.

      Descriptive analyses will be performed for all Severe Infections by Gram Negative Bacteria
      cases occurring among patients enrolled in this study.

      The study will be conducted in accordance with the ethical principles derived from the
      Declaration of Helsinki, the CGP and regulations.

      In this study the investigators will use the E-CRF in apposite web site. Data will be
      collected in E-CRF (electronic case report form) for the registration of clinical data
      through a special web portal dedicated to the study.

      Investigators are responsible for the preparation and storage of clinical data concerning
      the clinical trial in accordance with ICH guidelines for good clinical practice. Access to
      clinical data should be reserved exclusively to authorized personnel. Investigators will
      have to verify and ensure the strict confidentiality of records that could identify patients
      in compliance with standards on privacy and personal data in accordance with Italian
      legislation. On data collection forms (and related documentation) patients should be
      uniquely identified by date of birth and the code of enrolment. The full name of the patient
      will never be used in any communication and / or correspondence. Will be required direct
      access to the patient's original medical records for verification and monitoring of clinical
      data. The investigators are obliged to inform patients that their medical records could be
      verified, without breach of confidentiality of personal data. Investigators will have to
      allow monitoring of clinical data related to the study, the revisions IRB / IEC and
      inspections by regulatory authorities in accordance with Italian legislation, providing
      direct access to the medical records of patients.

      The national coordination of the study is carried out by the Office of Clinical Trials
      GITMO. The Office of Clinical Trials GITMO will act as the Data Management Center and
      quality control, providing for data management and administrative support throughout the
      course of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>4 Months</target_duration>
  <primary_outcome>
    <measure>incidence of each type of Severe Infections by Gram Negative Bacteria</measure>
    <time_frame>4 months by stem cell transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To estimate the incidence of each type of Severe Infections by Gram Negative Bacteria , in particular by antibiotic resistant isolates, documented during the engraftment period in patients submitted to autologous and allogeneic stem cell transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence particularly of Severe Infections by Gram Negative Bacteria</measure>
    <time_frame>4 months by stem cell transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the incidence of Severe Infections by Gram Negative Bacteria particularly those caused by antibiotic resistant enterobacteria in subgroups of patients undergoing autologous or allogeneic stem cell transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk factors</measure>
    <time_frame>4 month by stem cell transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the risk factors of Severe Infections by Gram Negative Bacteria particularly those caused by antibiotic resistant enterobacteria in autologous and allogeneic Stem cell CT transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic factors</measure>
    <time_frame>4 month by stem cell transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the prognostic factors of Severe Infections by Gram Negative Bacteria particularly those caused by antibiotic resistant enterobacteria in autologous and allogeneic Stem cell CT transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall mortality  for SIGNB</measure>
    <time_frame>3 months from the Severe Infections by Gram Negative Bacteria</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the overall Severe Infections by Gram Negative Bacteria and attributable mortality at 3 months from the SIGNB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival for SIGNB from transplant</measure>
    <time_frame>4 months from transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the impact of SIGNB on the overall survival at 4 months from transplant in autologous and allogeneic Stem Cell Transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>susceptibility pattern to antimicrobials of microorganisms</measure>
    <time_frame>4 month by stem cell transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the susceptibility pattern to antimicrobials of microorganisms causing Severe Infections by Gram Negative Bacteria with particular attention to enterobacteria with particular attention to the resistance phenotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibacterial strategies</measure>
    <time_frame>4 month by stem cell transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe the antibacterial strategies (in prophylaxis and therapy) employed in the various centers and in the various categories of patients particularly for the management of antibiotic resistant enterobacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local strategy</measure>
    <time_frame>4 month by stem cell transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the impact of a local strategy in the use of antibiotics on the epidemiology of Severe Infections by Gram Negative Bacteria</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Complications of Organ Transplant Stem Cells</condition>
  <condition>Gram-Negative Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>stem cell tranplant</arm_group_label>
    <description>All patients undergoing autologous or allogeneic stem cell tranplant for any underlying disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing autologous or allogeneic Stem Cell Transplant for any underlying
        disease will be monitored for SIGNB during the engraftment period.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All consecutive patients submitted to autologous or allogeneic SCT at the Centers
        participating to the survey Signed written informed consent according to IGH/EU/GCP and
        national local laws.

        Without age limit

        Exclusion Criteria:

        Patients who did not sign written informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrado Girmenia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Umberto I - Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corrado Girmenia, MD</last_name>
    <email>girmenia@bce.uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonia Mammoliti</last_name>
    <email>sonia.mammoliti@hsanmartino.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FPO Irccs</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Massimo Aglietta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera SS Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Teresa Corsetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica di Ematologia - Università Politecnica delle Marche</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Attilio Olivieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Mazzoni</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Piero Galieni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Bari-Ematologia con trapianti</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giorgina Specchia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Ospedali Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Orsola</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Arcangelo Prete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chiara Cattaneo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Spedali Civili di Brescia- USD - TMO Adulti</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Domenico Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Binaghi</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adriana Vacca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto - Ematologia</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giuseppe Milone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile USL 8</name>
      <address>
        <city>Civitanova Marche</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Riccardo Centurioni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicola Mordini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia - Azienda Ospedaliera di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alberto Bosi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elio Castagnola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU IRCCS San Martino - IST</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Bacigalupo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Corradini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabio Ciceri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IEO</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giovanni Martinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudio Annaloro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Risitano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INT IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gianpaolo Marcacci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale MAggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Ospedali Riuniti Villa Sofia - Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rosanna Scimè, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico La Maddalena</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maurizio Musso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CTMO Università</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Franco Aversa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marco P Zecca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Ematologia - IRCCS Policlinico S. Matteo - Università di Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emilio Paolo Alessandrino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. Medicina Clinica e Sperimentale</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Katia Perruccio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. di Ematologia - Unità di Terapia Intensiva Ematologica per il Trapianto Emopoietico - Ospedale Civile di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stella Santarone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale G. Da Saliceto di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniele Vallisa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giuseppe Irrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manuela Imola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Crob</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roberto Guariglia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simona Sica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia - Policlinico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corrado Girmenia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>William Arcese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paolo De Fabritiis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena IFO</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Mengarelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anna Chierichini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonella Ferrari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. San Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ignazio Majolino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambin Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Franco Locatelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica ed Ematologia - Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luca Castagna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia e Centro Trapianti Midollo Osseo - Ospedale IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. Giovanni Rotondo (FG)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Moscati</name>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giovanni Pisapia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Trapianti Metropolitano</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesca Carraro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alessandro Busca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Gonzaga</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniela Cilloni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Piero Maria Stefani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Panico</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vincenzo Pavone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Candoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simone Cesaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo-Divisione Ematologia</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roberto Raimondi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SIGNB</keyword>
  <keyword>severe infections gram negative bacteria</keyword>
  <keyword>stem cell transplant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
